がん悪液質市場レポート：療法、作用機序、流通チャネル、地域別、2025年～2033年

世界のがん悪液質の市場規模は2024年に22億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに30億米ドルに達し、2025年から2033年にかけて3.9%の成長率（CAGR）を示すと予測しています。この市場を牽引するのは、世界のがん罹患率の上昇、悪液質が患者の転帰に重大な影響を及ぼすという認識の高まり、患者のQOLと治療効果の向上を目的とした標的治療に関する研究の増加などです。

がん悪液質は、多因子性、宿主-貪食性、消耗性症候群を指し、組織的炎症、除脂肪体重の不随意的減少、負の蛋白バランス、食欲不振、筋萎縮を特徴とします。結核、多発性硬化症、慢性閉塞性肺疾患（COPD）、ヒト免疫不全ウイルス（HIV）など、さまざまな慢性疾患の発症によって引き起こされます。がん悪液質は、黄体ホルモン、コルチコステロイド、併用療法など、さまざまな治療薬を用いて治療することができます。このうち、黄体ホルモンは食欲を改善し、体重増加を促進する合成または天然のステロイドホルモンであり、副腎皮質ステロイドは炎症を緩和し、過剰な免疫系を抑制します。

がん悪液質市場動向：

がんや悪液質の有病率の増加、特に増加する高齢人口において、先進的な治療や薬剤の需要が促進されており、これが市場の成長を促進しています。これはさらに、がん悪液質を治療するための新規治療薬の利用可能性に関する消費者の意識の高まりにも支えられています。さらに、薬理学的、非薬理学的療法および臨床試験を通じて除脂肪体重（LBM）を改善するための併用療法に対する患者の傾向の変化は、もう一つの成長促進要因として作用しています。これに伴い、消化を改善するために酢酸メゲストロール、デキサメタゾン、メチルプレドニゾロンなどの食欲増進剤が広く利用されていることも、市場の成長に寄与しています。さらに、がん悪液質治療のための効果的な医薬品の開発に重点を置いた大幅な技術進歩が、市場の成長をさらに促進しています。これとは別に、がん悪液質の原因、症状、高度な治療を使用することの利点について人々を啓発するために、様々な国の政府機関や非政府組織（NGO）によって実施されている数多くの有利なイニシアチブが、市場に前向きな見通しを生み出しています。

本レポートで扱う主な質問

• 2024年のがん悪液質世界市場規模は？
• 2025年から2033年にかけてのがん悪液質世界市場の予想成長率は？
• がん悪液質の世界市場を牽引する主要因は？
• がん悪液質の世界市場におけるCOVID-19の影響は？
• がん悪液質の世界市場における療法別の区分は？
• がん悪液質の世界市場における作用機序別の区分は？
• がん悪液質の世界市場における主要地域は？
• 世界のがん悪液質市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のがん悪液質市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：療法別

• プロゲストーゲン
• コルチコステロイド
• 併用療法
• その他

第7章 市場内訳：作用機序別

• 食欲増進剤
• 減量安定剤

第8章 市場内訳：流通チャネル別

• 病院売店
• 小売薬局
• オンライン薬局

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場内訳：国別

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • AAVogen Inc.
  • Actimed Therapeutics Ltd.
  • Aphios Corporation
  • Artelo Biosciences Inc.
  • AVEO Pharmaceuticals Inc.
  • Fresenius Kabi AG（Fresenius SE & Co. KGaA）
  • Helsinn Healthcare SA
  • Merck & Co. Inc.
  • NGM Biopharmaceuticals Inc.
  • Pfizer Inc.
  • Tetra Bio-Pharma

List of Figures

• Figure 1: Global: Cancer Cachexia Market: Major Drivers and Challenges
• Figure 2: Global: Cancer Cachexia Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Cancer Cachexia Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Cancer Cachexia Market: Breakup by Therapeutics (in %), 2024
• Figure 5: Global: Cancer Cachexia Market: Breakup by Mode of Action (in %), 2024
• Figure 6: Global: Cancer Cachexia Market: Breakup by Distribution Channel (in %), 2024
• Figure 7: Global: Cancer Cachexia Market: Breakup by Region (in %), 2024
• Figure 8: Global: Cancer Cachexia (Progestogens) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Cancer Cachexia (Progestogens) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Cancer Cachexia (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Cancer Cachexia (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Cancer Cachexia (Combination Therapy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Cancer Cachexia (Combination Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Cancer Cachexia (Other Therapeutics) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Cancer Cachexia (Other Therapeutics) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Cancer Cachexia (Appetite Stimulators) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Cancer Cachexia (Appetite Stimulators) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Cancer Cachexia (Weight Loss Stabilizers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Cancer Cachexia (Weight Loss Stabilizers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Cancer Cachexia (Hospital Stores) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Cancer Cachexia (Hospital Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Cancer Cachexia (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Cancer Cachexia (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Cancer Cachexia (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Cancer Cachexia (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: North America: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: North America: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: United States: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: United States: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: Canada: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: Canada: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Asia-Pacific: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Asia-Pacific: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: China: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: China: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Japan: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Japan: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: India: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: India: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: South Korea: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: South Korea: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: Australia: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: Australia: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: Indonesia: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: Indonesia: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Others: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Others: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Europe: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Europe: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Germany: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Germany: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: France: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: France: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: United Kingdom: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: United Kingdom: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Italy: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Italy: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Spain: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Spain: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: Russia: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: Russia: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: Others: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: Others: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Latin America: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Latin America: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Brazil: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Brazil: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Mexico: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Mexico: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Others: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Others: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Middle East and Africa: Cancer Cachexia Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Middle East and Africa: Cancer Cachexia Market: Breakup by Country (in %), 2024
• Figure 74: Middle East and Africa: Cancer Cachexia Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 75: Global: Cancer Cachexia Industry: SWOT Analysis
• Figure 76: Global: Cancer Cachexia Industry: Value Chain Analysis
• Figure 77: Global: Cancer Cachexia Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Cancer Cachexia Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Cancer Cachexia Market Forecast: Breakup by Therapeutics (in Million USD), 2025-2033
• Table 3: Global: Cancer Cachexia Market Forecast: Breakup by Mode of Action (in Million USD), 2025-2033
• Table 4: Global: Cancer Cachexia Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 5: Global: Cancer Cachexia Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Cancer Cachexia Market: Competitive Structure
• Table 7: Global: Cancer Cachexia Market: Key Players

The global cancer cachexia market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.9% during 2025-2033. The market is driven by the rising global cancer incidence, the growing recognition of cachexia's significant impact on patient outcomes, and increased research into targeted therapies, all of which aim to enhance patient quality of life and treatment effectiveness.

Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.

Cancer Cachexia Market Trends:

The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials is acting as another growth-inducing factor. In line with this, the extensive utilization of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for improving digestion is also contributing to the market growth. Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms and benefits of using advanced treatments are creating a positive outlook for the market.

Key Market Segmentation:

Breakup by Therapeutics:

• Progestogens
• Corticosteroids
• Combination Therapy
• Others

Breakup by Mode of Action:

• Appetite Stimulators
• Weight Loss Stabilizers

Breakup by Distribution Channel:

• Hospital Stores
• Retail Pharmacy
• Online Pharmacy

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.

Key Questions Answered in This Report

• 1.What was the size of the global cancer cachexia market in 2024?
• 2.What is the expected growth rate of the global cancer cachexia market during 2025-2033?
• 3.What are the key factors driving the global cancer cachexia market?
• 4.What has been the impact of COVID-19 on the global cancer cachexia market?
• 5.What is the breakup of the global cancer cachexia market based on the therapeutics?
• 6.What is the breakup of the global cancer cachexia market based on the mode of action?
• 7.What are the key regions in the global cancer cachexia market?
• 8.Who are the key players/companies in the global cancer cachexia market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cancer Cachexia Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapeutics

• 6.1 Progestogens
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Corticosteroids
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Combination Therapy
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Mode of Action

• 7.1 Appetite Stimulators
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Weight Loss Stabilizers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Stores
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacy
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacy
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AAVogen Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Actimed Therapeutics Ltd.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Aphios Corporation
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Artelo Biosciences Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 AVEO Pharmaceuticals Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Fresenius Kabi AG (Fresenius SE & Co. KGaA)
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 SWOT Analysis
  • 14.3.7 Helsinn Healthcare SA
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Merck & Co. Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 NGM Biopharmaceuticals Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Pfizer Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Tetra Bio-Pharma
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials